CRISM Therapeutics Corporation (CRTX.L) Research

CRISM Therapeutics Corporation is dedicated to developing innovative drug delivery systems that enhance the effectiveness of cancer medications targeting solid tumors. Their primary offering, ChemoSeed, is designed for direct insertion into a tumor or the surgical site post-tumor removal, ensuring that therapeutic concentrations of chemotherapy agents are precisely localized to the cancerous tissue. This technology finds particular application in treating gliomas, a form of brain tumor. The company was established in 2016 and is headquartered in Road Town, British Virgin Islands.

Market snapshot

Symbol
CRTX.L
Price
$10.25
Day change
0.00%
Market cap
$4.0M
P/E ratio
-2.24x
52-week range
8-25
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 3 months

Peer companies

  • Chill Brands Group PLC (CHLL.L)
  • Cizzle Biotechnology Holdings Plc (CIZ.L)
  • Feedback plc (FDBK.L)
  • MyHealthChecked PLC (MHC.L)
  • N4 Pharma Plc (N4P.L)
  • Oxford BioDynamics Plc (OBD.L)
  • Proteome Sciences plc (PRM.L)
  • Roquefort Therapeutics plc (ROQ.L)

Open CRISM Therapeutics Corporation (CRTX.L) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.